Contrarian Take: This High-Yield Dividend Stock Is a Buy in May Despite Falling to an 11-Year Low

Clorox reported Q3 fiscal 2026 results that reinforced a weak operating backdrop, with fiscal 2026 organic sales now expected to decline 9% versus prior guidance for a 5% to 9% drop. Management cited pressure from competitor discounting and higher oil costs, which could trim quarterly gross profit by $20 million to $25 million, or about 130 bps of gross margin. Offsetting some of the weakness, Clorox completed its $2.25 billion GOJO acquisition, adding roughly $200 million of quarterly revenue and about 10% to total revenue, while the stock trades at 13.7x fiscal 2027 earnings and yields 5.7%.

Analysis

CLX is starting to look less like a simple earnings miss story and more like a portfolio architecture problem. When a staple company’s best growth and pricing power come from hygiene/cleaning, every dollar of managerial attention and capital tied up in slower, more price-elastic adjacencies becomes a drag on multiple expansion. The market is effectively telling management that “defensive” diversification only works if it improves elasticity-adjusted margin; otherwise it just dilutes the quality of the earnings stream.

The bigger second-order issue is channel behavior. If competitors are leaning into discounting, premium brands can either defend share and sacrifice gross margin, or preserve margin and accept volume leakage; CLX appears caught in the worst middle ground where it is spending enough to pressure profitability but not enough to reaccelerate share. That makes the next few quarters highly path-dependent: if promotions normalize, the stock can mean-revert quickly; if not, the dividend becomes the main support for valuation rather than a catalyst for re-rating.

GOJO is strategically sensible, but the market may be underestimating integration friction. Purell improves category focus, yet adding a meaningful acquired revenue base raises execution risk exactly when investor trust is fragile; synergies must arrive faster than consensus expects to offset the credibility deficit. The cleanest read-through is that CLX is moving toward a narrower, higher-quality product mix, but that transition likely suppresses headline growth before it improves it.

Contrarianly, the selloff may be overdone if management can prove that private label is not permanently taking share and that demand is still resilient at current price points. If the company delivers even one or two quarters of stable share with improving gross margin, the stock’s combination of yield and low expectations can force a sharp squeeze higher. The risk is that every guidance reset extends the multiple compression regime and turns a value stock into a value trap.

Key Decisions for Investors

• Avoid outright long CLX until management prints one clean quarter of stable guidance; the setup is better for confirmation than anticipation, with downside risk from another estimate cut still larger than near-term upside.
• If holding a consumer-staples basket, pair long PG / KMB versus short CLX over the next 3-6 months to isolate execution quality; CLX has more self-inflicted earnings risk while peers have cleaner pricing power and less portfolio noise.
• For event-driven accounts, consider a small CLX call spread 3-6 months out only if shares sell off on any additional guidance reset; the asymmetric setup is a post-capitulation rebound, not a pre-earnings momentum trade.
• Monitor CLX as a dividend defense name rather than a growth name; if the yield continues to compress the equity risk premium without any guidance stabilization, that is a warning sign to exit rather than average down.
• Look for a rotation into hygiene-exposed suppliers or contract manufacturers that benefit if CLX/GOJO rationalize SKUs and simplify the portfolio; the second-order winner is likely in the supply chain, not necessarily in the branded equity itself.